Locations
Spanish Global Health Strategy 2025-2030
Last week, the Spanish government approved the new Global Health Strategy 2025-2023 (EESG), which has been promoted by the Ministries of Foreign Affairs, European Union and Cooperation, and Health.
With this initiative, Spain aims to strengthen cooperation with various international actors at all levels, both state and non-state, with the aim of promoting global health governance based on multilateralism and shared management and financing structures, with the World Health Organization (WHO) at the center of this system.
The EESG has six fundamental objectives:
-
Strengthen public and resilient health systems.
-
Promote health and well-being from a course life approach.
-
Address the health impacts of climate change in a comprehensive manner.
-
Prepare for cross-border health emergencies and threats.
-
Strengthen global health governance and architecture.
-
Promote research, innovation, and digitalization in health with a focus on equity.
Inclusion of new smoke-free spaces in the future reform of the Tobacco Law
The Ministry of Health is currently working on reforming the Tobacco Law, which will include an expansion of smoke-free public spaces, including restaurant terraces, university campuses, educational centers, sports facilities, transportation shelters, work vehicles, and outdoor leisure areas.
The aim of this measure is to protect the population, especially vulnerable groups such as minors and pregnant women, and to denormalize tobacco consumption in shared spaces.
2024 Activity Report of the Spanish Agency of Medicines and Medical Devices
Last week, the Spanish Agency of Medicines and Medical Devices (AEMPS) presented its 2024 Activity Report, which summarizes the work carried out by the AEMPS during 2024.
Among the tasks included in the report, the following stand out:
-
Spain is once again the world leader in clinical trials, as well as the European country with the most studies authorized in a year of great regulatory complexity with the definitive implementation of the European Clinical Trials Regulation.
-
Participation of the AEMPS in the largest suspension of medicines in the EU.
-
The role of the AEMPS in the management and control of bluetongue and epizootic hemorrhagic disease in the EU, which has been decisive due to its rapid response to a new virus serotype for which no vaccine is available in the EU, and in facilitating early access to vaccination and subsequent immunization of sheep, goats, and cattle.
-
AEMPS involvement in the significant regulatory change affecting tattoo inks and permanent makeup, which are considered personal care products.